Mr. Dan Legault reports
ANTIBE THERAPEUTICS PROVIDES AN UPDATE ON ITS DATA REVIEW AND CORPORATE STRATEGY
Antibe
Therapeutics Inc. has completed the process of collecting and reviewing its phase
1 data, further to its Jan. 16, 2015, news release. As a result,
Antibe has resumed the development of ATB-346.
ATB-346's pharmacokinetic profile, coupled with data on cyclooxygenase
inhibition in humans (an efficacy biomarker), suggests a target
therapeutic dose at or below 250 milligrams daily, a much lower level than
initially anticipated. It also provides a possible explanation for the
safety issues observed at the 750-milligram and 1,500-milligram doses. At a dose of 250
milligrams given once daily for 14 days, ATB-346 was safe and well tolerated in
the phase 1 study.
Accordingly, the company has concluded its phase 1 study and plans to
conduct additional validating studies prior to continuing with a full
phase 2 program. The company has made significant reductions in its
overheads and will concentrate its resources on completing the above
studies.
We seek Safe Harbor.
© 2024 Canjex Publishing Ltd. All rights reserved.